Head and Neck Cancer Immunology

Our group focuses on Head and Neck squamous cell carcinoma (HNSCC) which is the 8th most common cancer worldwide, with a 5-year survival rate of 50%. 

Patients are currently treated with surgery, radio-, chemo-, targeted- and immune- therapy, but with poor results and major side effects. 

The urgency of finding a better way to treat HNSCC patients, is what drives our efforts to better understand the tumor immune environment and search for new treatment strategies.